PE20141040A1 - Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica - Google Patents

Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica

Info

Publication number
PE20141040A1
PE20141040A1 PE2013002762A PE2013002762A PE20141040A1 PE 20141040 A1 PE20141040 A1 PE 20141040A1 PE 2013002762 A PE2013002762 A PE 2013002762A PE 2013002762 A PE2013002762 A PE 2013002762A PE 20141040 A1 PE20141040 A1 PE 20141040A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
growth
inhibits
metallic salt
composition including
Prior art date
Application number
PE2013002762A
Other languages
English (en)
Inventor
Yong Il Kim
Kyeong Soo Kim
Jin Cheul Kim
Yo Han Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20141040A1 publication Critical patent/PE20141040A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/604—Polycarboxylic acid esters, the acid moiety containing more than two carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Charge And Discharge Circuits For Batteries Or The Like (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO DE FORMULA (I), Y B) UN LUBRICANTE DE SAL NO METALICA SELECCIONADO DE ACIDOS GRASOS, ACIDO FUMARICO, ALCOHOLES GRASOS, POLIETILENGLICOLES, POLITETRAFLUOROETILENOS, ENTRE OTROS. ADEMAS LA COMPOSICION FARMACEUTICA COMPRENDE UN ADITIVO TAL COMO UN DILUYENTE, UN ALGUTINANTE, UN DESINTEGRANTE Y UNA MEZCLA DE LOS MISMOS. REFERIDO ADEMAS A UN METODO PARA PREPARAR UNA FORMULACION DE LA COMPOSICION FARMACEUTICA. DICHA COMPOSICION FARMACEUTICA INHIBE EL CRECIMIENTO DE CELULAS CANCEROSAS
PE2013002762A 2011-06-07 2012-05-18 Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica PE20141040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110054685A KR101317809B1 (ko) 2011-06-07 2011-06-07 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
PE20141040A1 true PE20141040A1 (es) 2014-09-08

Family

ID=47296259

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002762A PE20141040A1 (es) 2011-06-07 2012-05-18 Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica

Country Status (26)

Country Link
US (2) US9731022B2 (es)
EP (1) EP2718282B1 (es)
JP (1) JP6030643B2 (es)
KR (1) KR101317809B1 (es)
CN (1) CN103596940B (es)
AR (1) AR086851A1 (es)
AU (1) AU2012267642C1 (es)
BR (1) BR112013030456B1 (es)
CA (2) CA3053181A1 (es)
CL (1) CL2013003513A1 (es)
CO (1) CO6852070A2 (es)
DK (1) DK2718282T3 (es)
EC (1) ECSP14013121A (es)
ES (1) ES2625268T3 (es)
IL (1) IL229739B (es)
MA (1) MA35405B1 (es)
MX (3) MX361129B (es)
MY (1) MY166949A (es)
PE (1) PE20141040A1 (es)
PH (1) PH12013502542B1 (es)
PT (1) PT2718282T (es)
RU (1) RU2632099C2 (es)
TW (1) TWI617307B (es)
UA (1) UA112545C2 (es)
WO (1) WO2012169733A1 (es)
ZA (1) ZA201400051B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
EP2878453A1 (de) 2013-11-28 2015-06-03 Authentic Vision GmbH Objektmarkierung zur optischen Authentifizierung und Verfahren zu deren Herstellung
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101669240B1 (ko) * 2015-03-12 2016-10-25 아주대학교산학협력단 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법
WO2017115746A1 (ja) * 2015-12-28 2017-07-06 沢井製薬株式会社 ゲフィチニブ含有錠剤
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
SG11202009498RA (en) * 2018-03-27 2020-10-29 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
BR112021004527A2 (pt) * 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
JP7700043B2 (ja) * 2019-03-29 2025-06-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
KR102254307B1 (ko) * 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물
KR102812658B1 (ko) * 2019-10-24 2025-05-26 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
CN114502144A (zh) * 2019-10-24 2022-05-13 韩美药品株式会社 包含抑制癌细胞生长的酰胺衍生物的药物制剂以及包含其的药物产品

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02275891A (ja) * 1988-12-29 1990-11-09 Tsumura & Co 新規な複核白金錯体および該錯体を有効成分とする抗腫瘍剤
AU699224B2 (en) 1994-08-23 1998-11-26 Smithkline Beecham Plc Improved pharmaceutical formulations containing ibuprofen and codeine
KR980008219A (ko) 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
KR980008219U (ko) 1996-07-31 1998-04-30 배순훈 세탁기의 구동모터 냉각팬
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP3687025B2 (ja) 1998-06-04 2005-08-24 東和薬品株式会社 安定なマレイン酸エナラプリル錠剤
US7709479B1 (en) 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2476008C (en) 2002-03-30 2011-12-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CN1882570B (zh) 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
KR20060100388A (ko) 2003-09-25 2006-09-20 아스트라제네카 아베 퀴나졸린 유도체
DE10345875A1 (de) 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
CA2619037A1 (en) 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
BRPI0619603A2 (pt) 2005-12-12 2011-10-11 Boehringer Ingelheim Int heterociclos bicìclicos, sais fisiologicamante compatìveis, medicamentos que contêm esses compostos, bem como uso e processos para produção dos heterociclos bicìclicos
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
ATE464881T1 (de) 2006-04-13 2010-05-15 Riemser Specialty Production Gmbh Partialglyceride als schmiermittel für pharmazeutische zusammensetzungen enthaltend thienoä3,2-cüpyridin-derivate
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2178512B1 (en) 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
MY144136A (en) 2009-04-20 2011-08-10 Univ Sains Malaysia Throttle and brake lock
AU2010273319B2 (en) * 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
CN102822676B (zh) * 2010-01-12 2015-02-18 雀巢产品技术援助有限公司 用于预测三阴性乳腺癌对疗法的应答的方法
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체

Also Published As

Publication number Publication date
BR112013030456B1 (pt) 2022-08-02
MY166949A (en) 2018-07-25
UA112545C2 (uk) 2016-09-26
EP2718282A1 (en) 2014-04-16
RU2013158858A (ru) 2015-07-20
TW201302201A (zh) 2013-01-16
JP6030643B2 (ja) 2016-11-24
MX382470B (es) 2025-03-13
WO2012169733A1 (en) 2012-12-13
ECSP14013121A (es) 2014-02-28
AR086851A1 (es) 2014-01-29
CO6852070A2 (es) 2014-01-30
RU2632099C2 (ru) 2017-10-02
US20140112962A1 (en) 2014-04-24
US9931406B2 (en) 2018-04-03
CN103596940B (zh) 2017-09-12
US20170340744A1 (en) 2017-11-30
AU2012267642C1 (en) 2017-11-16
KR101317809B1 (ko) 2013-10-16
CN103596940A (zh) 2014-02-19
BR112013030456A2 (pt) 2016-09-27
CA2837703A1 (en) 2012-12-13
IL229739A0 (en) 2014-01-30
TWI617307B (zh) 2018-03-11
NZ619606A (en) 2015-07-31
KR20120135777A (ko) 2012-12-17
PT2718282T (pt) 2017-05-25
MX361129B (es) 2018-11-28
CL2013003513A1 (es) 2014-09-26
EP2718282B1 (en) 2017-03-15
MX2013013997A (es) 2014-06-23
ZA201400051B (en) 2015-04-29
MX2021005494A (es) 2022-06-08
AU2012267642A1 (en) 2014-01-30
JP2014516082A (ja) 2014-07-07
CA3053181A1 (en) 2012-12-13
DK2718282T3 (en) 2017-05-22
IL229739B (en) 2018-01-31
ES2625268T3 (es) 2017-07-19
PH12013502542A1 (en) 2014-02-10
EP2718282A4 (en) 2015-04-15
CA2837703C (en) 2019-09-24
AU2012267642B2 (en) 2017-04-20
PH12013502542B1 (en) 2018-07-11
US9731022B2 (en) 2017-08-15
MA35405B1 (fr) 2014-09-01

Similar Documents

Publication Publication Date Title
PE20141040A1 (es) Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
ES2563323T3 (es) Procedimiento para la preparación de un sólido cristalino a partir de derivados de ácido glicin-N,N-diacético
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
AR081870A1 (es) Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo
CA2875877C (en) Syk inhibitors
AR085507A1 (es) Animales modificados geneticamente y metodos para su obtencion
CU23847B1 (es) 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
CO6541606A2 (es) Espiroindolinona- pirrolidinas
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR088018A1 (es) Proceso e intermediarios para preparar lapatinib
PE20141554A1 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparacion, preparados farmaceuticos que los contienen, asi como su uso para la preparacion de medicamentos
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
MX337320B (es) Análogos halogenados de agentes anti-fibroticos.
ES2585077T3 (es) Procedimientos para la preparación de 6-cloro-2,3,4,9-tetrahidro-1H-carbazol-1-carboxamida y de sus precursores
PE20170212A1 (es) Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX2014000344A (es) Antagonistas de trpv1 que incluyen sustituyente dihidroxi y sus usos.
WO2012071562A3 (en) Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound

Legal Events

Date Code Title Description
FG Grant, registration